TABLE 2.

Results of drug sensitivity testing of HSV-1 clinical isolates from patient 708

Patient agea (yrs)Site of swabIC50 (μg/ml)b of:Last recorded therapy
ACVFoscarnet
18.84Skin1322ACV and foscarnet
18.79Left inguinal area0.514Foscarnet
14.39Labium3.219ACV
14.39Abdomen1.916ACV
13.67Chin0.127Foscarnet
13.62Face0.248Foscarnet
13.10Vagina3.9NRACV
13.10Vagina1.8NRACV
  • a Age at which the corresponding swab sample was taken.

  • b Resistance is defined as an IC50 of ACV of ≥2 μg/ml and an IC50 of foscarnet of ≥150 μg/ml. NR, not recorded.